Key result
Life-long antithrombotic therapy may be required in a considerable number of patients to prevent or treat occlusive vascular diseases even after intracerebral hemorrhage.
Why the study?
Many ICH patients have accompanying ischemic stroke or coronary artery disease requiring lifelong antithrombotic therapy to prevent or treat occlusive vascular diseases.
Is restarting antiplatelet therapy safe and effective in patients after intracerebral hemorrhage?
Is restarting antiplatelet therapy safe and effective in patients after intracerebral hemorrhage?
This paper discusses the clinical dilemma of restarting antiplatelet therapy in patients who have experienced an intracerebral hemorrhage but have concurrent occlusive vascular disease.
Restarting antiplatelet therapy after ICH was not associated with higher recurrent hemorrhage risk; leaves open net clinical benefit for ischemic prevention.
Intracerebral hemorrhage (ICH) develops as a result of bleeding from a small arterial rupture and can be included in the category of cerebral small vessel disease (1,2). Because the risk factors for ICH such as advanced age, hypertension, and cigarette smoking are also those for occlusive vascular diseases (3), many ICH patients have an accompanying ischemic stroke or coronary artery disease, which are significant causes of long-term morbidity and mortality in these cases (4-6). Hence, life-long antithrombotic therapy may be required in a considerable number of patients to prevent or/and treat occlusive vascular diseases even after ICH.
No takes yet. Share an insight, caveat, or question.
Eun et al. (2019) conducted a review in Intracerebral hemorrhage. Restarting antiplatelet therapy was evaluated. Life-long antithrombotic therapy may be required in a considerable number of patients to prevent or treat occlusive vascular diseases even after intracerebral hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: